Page 46 - PRESENTATION

Testosterone suppression in the treatment of recurrent or

metastatic prostate cancer – A Canadian consensus statement

2
3
4
1
Laurence Klotz, MD, FRCSC ; Bobby Shayegan, MD, FRCSC ; Chantal Guillemette, PhD ; Loretta L. Collins, PhD ; Geoffrey Gotto, MD, MPH,
3
5
7
FRCSC ; Dominique Guérette, PhD, CSPQ, FCACB ; Marie-Paule Jammal, MD, FRCSC ; Tom Pickles, MD, FRCPC ; Patrick O. Richard, MD,
6
8
MSc, FRCSC ; Fred Saad, MD, FRCSC 9

• Testosterone levels during ADT reflect efficacy of treatment, while serum PSA

is a reflection of disease control.

• Treatment goal is to get and keep testosterone levels ≤0.7 nmol/L within the first year in

order to maintain PSA ≤2 ng/mL

• If either begin to rise, then reassessment and a change in treatment may be

warranted

• Considerations for iADT vs cADT….

47 Klotz L, Shayegan B, Guillemette C, Collins L et al. Can Urol Assoc J 2018;12(2):30-7. http://dx.doi.org/10.5489/cuaj.5116